^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Perjeta (pertuzumab)

    i
    Other names: RG1273, rhuMAb 2C4 , R 1273, R-1273, R1273, RG 1273, rhuMab2C4, Ro 436-8451/F01, RO-4368451-F01, RO4368451, rhuMab-2C4
    Company:
    Roche
    Drug class:
    HER2 dimerization inhibitor
    Related drugs:
    1d
    Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. (clinicaltrials.gov)
    P2, N=30, Enrolling by invitation, Zhejiang Provincial People's Hospital
    New P2 trial
    |
    Perjeta (pertuzumab) • Lenvima (lenvatinib)
    2d
    Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Rutgers, The State University of New Jersey | Not yet recruiting --> Recruiting
    Enrollment open • Biomarker assay • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)
    3d
    Real-World Study of First-Line Treatment with Trastuzumab Biosimilar and Pertuzumab Biosimilar Combined with Chemotherapy in Patients with HER2-Positive Breast Cancer (ChiCTR2600121627)
    P=N/A, N=1500, Recruiting, The Second Qilu Hospital of Shandong University; The Second Qilu Hospital of Shandong University
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification
    |
    Perjeta (pertuzumab)
    3d
    A single-arm, phase II, exploratory study of neoadjuvant treatment with Kudosil combined with Culmerciclib and dual-targeted therapy of trastuzumab and pertuzumab in HR+, HER2+ breast cancer (ChiCTR2600121242)
    P2, N=28, Recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital); The First Affiliated Hospital of Nanjing Medical U
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • letrozole • Saitanxin (culmerciclib)
    3d
    Trastuzumab and pertuzumab in combination with eribulin mesylate as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer: a prospective, single-arm, phase II clinical trial (ChiCTR2600120346)
    P4, N=40, Recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Halaven (eribulin mesylate)
    3d
    A Prospective, Multicenter, Single-Arm Clinical Study of Atezolizumab Combined with SHR-A1811and Pertuzumab in the Neoadjuvant Treatment of HER2-Positive Breast Cancer (ChiCTR2600118900)
    P2, N=50, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    3d
    A Randomized, Open-Label Trial of Trastuzumab Combined with Pyrotinib and Taxanes (THPy) versus Trastuzumab Combined with Pertuzumab and Taxanes (THP) as First‑Line Treatment for Advanced HER2‑Positive Breast Cancer (ChiCTR2500101511)
    P4, N=568, Recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)
    4d
    A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P2 trial
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • anbenitamab repodatecan (JSKN003)
    5d
    PERTUREAL: Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Société Algérienne de Formation et Recherche en Oncologie
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Perjeta (pertuzumab)
    5d
    A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer. (PubMed, Sci Rep)
    The HER2 inhibitors represent different mechanisms of actions, including trastuzumab, pertuzumab, tucatinib, and lapatinib, all of which are clinically approved, as well as PEPDG278D, a recombinant human protein which was previously shown to induce the degradation of HER2 and epidermal growth factor receptor (EGFR). Despite p95HER2 expression and resistance to current HER2 inhibitors, HER2-positive BC cells and tumors are highly vulnerable to PEPDG278D-induced degradation of HER2 and EGFR. By inducing HER2 degradation, PEPDG278D eliminates p95HER2 in HER2-positive BC cells and tumors.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression • EGFR positive
    |
    Herceptin (trastuzumab) • lapatinib • Perjeta (pertuzumab) • Tukysa (tucatinib)
    5d
    A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant Therapy (clinicaltrials.gov)
    P=N/A, N=2000, Not yet recruiting, Hebei Medical University Fourth Hospital
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Perjeta (pertuzumab)
    5d
    Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, The Methodist Hospital Research Institute | N=39 --> 51 | Trial completion date: Dec 2025 --> Dec 2028
    Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • PD-L1 negative
    |
    BluePrint
    |
    Herceptin (trastuzumab) • Imfinzi (durvalumab) • Perjeta (pertuzumab)